| Document |
Document Title |
|
WO/2015/002230A1 |
The present invention relates to compounds (I), which have RORγt inhibitory effects, and salts thereof. In formula (I), each notation is as described in the Specification. (I)
|
|
WO/2015/000833A1 |
The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions fo...
|
|
WO/2014/201016A2 |
Provided herein are compounds of the formula (IV) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...
|
|
WO/2014/197860A1 |
Methods of making monomethyl fumarate, which can then also be used in methods of making prodrugs of monomethyl fumarate, are disclosed. Monomethyl fumarate and prodrugs of monomethyl fumarate are useful for treating neurodegenerative, in...
|
|
WO/2014/192865A1 |
The present invention relates to a therapeutic agent for neurodegenerative diseases and mental diseases, which comprises, as an active ingredient, a compound represented by formula (1) [wherein Z1 represents a halogen atom, an alkyl grou...
|
|
WO/2014/191548A1 |
The present invention provides a new synthetic process for the production of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine (vortioxetine), an experimental drug under development for the treatment of depression and anxiety, which compr...
|
|
WO/2014/185279A1 |
This carbamic acid ester compound is represented by formula (1). (In the formula, R1 is a group having OH removed from alcohol R1OH having a boiling point of 250°C or lower at one atm. R2 and R3 are each independently a hydrogen atom or...
|
|
WO/2014/184039A1 |
The invention relates to a method for preparing an N-alkyl-piperazine of formula I, wherein R1 is hydrogen (H), methyl or ethyl and R2 is C1 to C5 alkyl, by reacting an N-substituted diethanolamine of formula II with ammonia or a primary...
|
|
WO/2014/184048A1 |
The invention relates to a method for preparing an N-alkyl-piperazine of formula I, wherein R1 is hydrogen (H), methyl or ethyl and R2 is C1 to C5 alkyl, by reacting an N-substituted diethanolamine (DEOA) of formula II with ammonia or a ...
|
|
WO/2014/180455A1 |
The invention relates to a method of preparation of 2-oxoglutarate ester, a preparation containing 2-oxoglutarate ester and use thereof for supporting collagen biosynthesis.
|
|
WO/2014/182673A1 |
The present invention relates to compounds of Formula (la) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the Mas receptor, and are useful in methods of treatment and alleviation of d...
|
|
WO/2014/100762A9 |
The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the ...
|
|
WO/2014/178284A1 |
A thermoelectric conversion element which has a first electrode, a thermoelectric conversion layer and a second electrode on a base, and wherein the thermoelectric conversion layer contains a conductive nano-material and at least one com...
|
|
WO/2014/177491A1 |
Title: New Solid Form of 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine Hydrobromide The present invention relates to 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine hydrobromide (vortioxetine hydrobromide,a drug for the treatment of ...
|
|
WO/2014/178389A1 |
Provided is a new compound having glycogen synthase activation potency, high muscular transition, minimal activation of receptor PPAR, and a high degree of safety. Provided is a compound represented by the following general formula, or a...
|
|
WO/2014/178381A1 |
Provided is a new compound having glycogen synthase activation potency, but minimal activation of receptor PPAR, and a high degree of safety. A compound represented by general formula [I], or a pharmaceutically acceptable salt thereof....
|
|
WO/2014/175317A1 |
The problem is to provide a pharmaceutical for the prevention or treatment of hyperphosphatemia. Solution: A compound having general formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, R1: methyl group or the like...
|
|
WO/2014/165827A1 |
Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demye...
|
|
WO/2014/163106A1 |
The present invention provides a compound represented by formula (I) (wherein R1 represents CH3, F, (CH2)n-F, NH-(CH2)n-F, O-(CH2)n-F or S-(CH2)n-F; and n represents an integer of 1 to 3).
|
|
WO/2014/161976A1 |
The present invention provides new intermediate compounds or formulae (III) and (IVa), and salts thereof, and their use in a new synthetic process for the production of 1-(2-((2,4- dimethylphenyl)thio)phenyl)piperazine (vortioxetine) an ...
|
|
WO/2014/156196A1 |
The present invention addresses the problem of providing a novel therapeutic agent for patients with type 2 diabetes, one of the causes thereof being abnormal synthesis of insulin due to aberrant modification of tRNALys(UUU) in a pancrea...
|
|
WO/2014/147642A1 |
The present invention relates to novel donor-acceptor fluoranthenes of the general formula I which can be used potentially in developing fluorescent probes, and a process of preparing said novel compounds. More particularly, the present ...
|
|
WO/2014/133041A1 |
An embodiment of the present invention relates to cellulose acylate film comprising a compound represented by general formula (I) and having a molar weight U of 515 or less, which is determined as the value obtained by dividing the molec...
|
|
WO/2014/128207A1 |
A process for the manufacture of vortioxetine is provided in which a compound of formula I, formula I is reacted with optionally substituted piperazine and 2,4-dimethylthiophenol(ate) followed by de-complexation.
|
|
WO/2014/125410A1 |
The present invention provides N-substituted novel heterocyclic derivatives of formula (I) as protein kinase inhibitors, in which R1, R2 and 'n' have the same meanings given in the specification, and pharmaceutically acceptable salts the...
|
|
WO/2014/124892A1 |
The present invention relates to a method for synthesising ionic liquids comprising a carbonate functional group characterized in that it comprises a reaction step A without addition of lithium between a first reactant chosen from an imi...
|
|
WO/2014/125075A1 |
The present invention relates to a antibiotically active compounds characterized by general formula (I), wherein X1, BB, BC, BD, BE and X2 are building blocks with D1, D2, D3, D4 or D5 being linkers which comprise carbon, sulphur, nitrog...
|
|
WO/2014/122670A1 |
The present invention relates to the synthesis and biological evaluation of compound of formula I as spermicidal agents, and its pharmaceutically acceptable acid salt thereof. The invention provides bis(4- substituted-1-piperazinylthioca...
|
|
WO/2014/121884A1 |
The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states...
|
|
WO/2014/122303A1 |
The present invention provides compounds with anti-fungal activity useful for treatment or prevention of fungal infections in human beings or plants. The antifungal compounds are inhibitors of glucan synthase and have the formula (I) (I)...
|
|
WO/2014/118042A1 |
The invention relates to the hydroaminomethylation of olefins, an olefin being reacted with at least one primary or secondary amine, with the addition of H2 and CO in the presence of a catalytic system consisting of a ruthenium complex a...
|
|
WO/2014/118038A1 |
The invention relates to novel phosphorus ligands and to a chemoselective and regioselective method for the hydroaminomethylation of olefins with at least one primary or secondary amine, with the addition of H2 and CO under catalytic con...
|
|
WO/2014/115813A1 |
The purpose of the present invention is to provide new organic phosphorus-based ligands that can efficiently perform a cross coupling reaction to obtain a target substance with high yield; and also to provide a manufacturing method that ...
|
|
WO/2014/112646A1 |
The present invention addresses the problem of providing a compound having a selective inhibitory activity on LAT-1 that can be expressed in a tumor cell at a high level. The present invention provides: a compound represented by formula ...
|
|
WO/2014/110103A1 |
The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the histamine H3 receptor (Ia). Compounds of the present invention and pharma...
|
|
WO/2014/110491A1 |
Prodrugs of treprostinil are provided which can be used in the treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable...
|
|
WO/2014/110329A1 |
The present invention relates to anhydrous tetraalkyl pnictogen perfluoroalkoxy salts and a process to produce anhydrous tetraalkyl pnictogen perfluoroalkoxy salts. The process involves contacting a hydrofluoroether and an amine to produ...
|
|
WO/2014/108629A1 |
The invention relates to a compound having general formula (I) and the pharmaceutically acceptable salt thereof, and to the use of said compound for cosmetic or pharmaceutical uses.
|
|
WO/2014/108671A1 |
A method of preparing a 2,6 disubstituted anilines includes, reacting a 2-amino isophtha!ic acid diester with sufficient Grignard reagent R2CH2MgX to form the corresponding diol product, dehydrating the diol product to the corresponding ...
|
|
WO/2014/104272A1 |
The present invention provides a cinnamic acid amide derivative having an excellent analgesic activity. The cinnamic acid amide derivative according to the present invention is a compound that exhibits an excellent analgesic activity on ...
|
|
WO/2014/105764A1 |
Disclosed herein are beta-amino ester surfactant compounds and compositions useful in applications relating to inhibition of gas hydrate agglomerates in the production, transportation, storage, and separation of crude oil and natural gas...
|
|
WO/2014/101690A1 |
The present invention relates to the field of pharmaceutical synthesis, and specifically, to a method for preparing an Ezetimibe chiral intermediate. The method is as follows: a method for preparing a compound with a formula (b) structur...
|
|
WO/2014/099261A1 |
A molecular sieve having the framework structure of ZSM-5 is produced using one or more of l,4-bis(N-pentylpyrrolidinium)butane dications, l,5-bis(N- pentylpyrrolidinium)pentane dications, and l,6-bis(N-pentylpyrrolidinium)hexane dicatio...
|
|
WO/2014/096378A1 |
The present invention concerns a compound of general formula (I) in which n = 0 or 1, R1 represents an optionally substituted alkyl chain, in particular substituted with fluorine, X is chosen from N and CH, and R2 is chosen from phenyl a...
|
|
WO/2014/094658A1 |
Provided are new compounds of tert-butylphenyl-2-methyl-2-(1-piperidinyl)-1-propanone and tert-butylphenyl-2-methyl-2-(1-morpholinyl)-1-propanone, a preparation method therefor and the use of same as a photoinitiator. Also disclosed are ...
|
|
WO/2014/093231A2 |
The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infecti...
|
|
WO/2014/090712A1 |
Compounds of the formula Ia or Ib, or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of making the compounds...
|
|
WO/2014/092194A1 |
The photosensitive layer of an electrophotographic photosensitive member contains a phthalocyanine crystal in which a compound represented by the following formula (1) is contained:
|
|
WO/2014/083384A1 |
Benzenesulfonamide compounds potentiate 2,4-D induced embryogenesis in plants. In particular, 4-chloro-N-methyl-N-(2-methylphenyl) benzenesulfonamide and analogs induce somatic embryogenesis in plants. Methods of inducing somatic embryog...
|
|
WO/2014/084298A1 |
The present invention mainly addresses the problem of providing a novel compound having a LSD1-selective inhibitory activity and also having an anti—tumor/anti-cancer activity, an anti-virus activity and the like. As a means for solvin...
|
